Pharmacyclics
| Company type | Subsidiary |
|---|---|
| Nasdaq: PCYC | |
| Industry | Biopharmaceutical |
| Founded | 1991 |
| Founders | Jonathan Sessler, Richard A. Miller |
| Headquarters | Sunnyvale, California |
Area served | Worldwide |
Key people | Robert Duggan, former CEO and Chairman |
| Revenue | US$235 million (2013) |
| US$110 million (2013) | |
| US$86.1 million (2013) | |
| Total assets | US$1.06 billion (2013) |
| Total equity | US$829 million (2013) |
| Parent | AbbVie |
| Website | pharmacyclics |
Pharmacyclics LLC is an American biopharmaceutical company based in Sunnyvale, California. It is primarily focused on the development of cancer therapies. In 2017, Xynomic Pharmaceuticals acquired all global rights to Abexinostat, Pharmacyclics' primary commercial product.